← Back to Screener
Lineage Cell Therapeutics, Inc. (LCTX)
Price$1.64
Favorite Metrics
Price vs S&P 500 (26W)-9.77%
Price vs S&P 500 (4W)2.84%
Market Capitalization$406.01M
All Metrics
Book Value / Share (Quarterly)$0.18
P/TBV (Annual)29.94x
Revenue Growth (3Y)-0.33%
Cash Flow / Share (Quarterly)$-0.08
Price vs S&P 500 (YTD)-5.04%
Gross Margin (TTM)99.00%
Net Profit Margin (TTM)-436.47%
EPS (TTM)$-0.28
10-Day Avg Trading Volume1.02M
EPS Excl Extra (TTM)$-0.28
Revenue Growth (5Y)51.40%
EPS (Annual)$-0.28
ROI (Annual)-142.39%
Gross Margin (Annual)99.00%
Net Profit Margin (5Y Avg)-408.50%
Cash / Share (Quarterly)$0.23
Revenue Growth QoQ (YoY)130.40%
ROA (Last FY)-56.43%
Revenue Growth TTM (YoY)53.24%
EBITD / Share (TTM)$-0.31
ROE (5Y Avg)-56.55%
Operating Margin (TTM)-251.57%
Cash Flow / Share (Annual)$-0.08
P/B Ratio9.11x
P/B Ratio (Quarterly)8.63x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)25.10x
Net Interest Coverage (TTM)-17.84x
ROA (TTM)-62.78%
EV / EBITDA (TTM)9.71x
EPS Incl Extra (Annual)$-0.28
Current Ratio (Annual)5.20x
Quick Ratio (Quarterly)4.99x
3-Month Avg Trading Volume1.15M
52-Week Price Return270.45%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)27.89x
Asset Turnover (Annual)0.13x
52-Week High$2.09
Operating Margin (5Y Avg)-405.85%
EPS Excl Extra (Annual)$-0.28
CapEx CAGR (5Y)54.14%
Tangible BV CAGR (5Y)-23.52%
26-Week Price Return-5.78%
Quick Ratio (Annual)4.99x
13-Week Price Return-7.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.20x
Enterprise Value$365.291
Revenue / Share Growth (5Y)39.00%
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)-21.83%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.40x
Pretax Margin (Annual)-471.61%
Cash / Share (Annual)$0.23
3-Month Return Std Dev61.85%
Gross Margin (5Y Avg)90.07%
Net Income / Employee (TTM)$-1
ROE (Last FY)-142.61%
Net Interest Coverage (Annual)-12.40x
EPS Basic Excl Extra (Annual)$-0.28
P/FCF (TTM)18.58x
Receivables Turnover (TTM)19.04x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.28
Receivables Turnover (Annual)19.04x
ROI (TTM)-130.75%
P/S Ratio (TTM)27.89x
Pretax Margin (5Y Avg)-420.02%
Revenue / Share (Annual)$0.06
Tangible BV / Share (Annual)$0.05
Price vs S&P 500 (52W)240.62%
Year-to-Date Return-2.40%
5-Day Price Return9.40%
EPS Normalized (Annual)$-0.28
ROA (5Y Avg)-28.01%
Net Profit Margin (Annual)-436.47%
Month-to-Date Return3.16%
Cash Flow / Share (TTM)$-0.13
EBITD / Share (Annual)$-0.31
Operating Margin (Annual)-251.57%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-56.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.28
P/TBV (Quarterly)29.94x
P/B Ratio (Annual)8.63x
Inventory Turnover (TTM)7.40x
Pretax Margin (TTM)-471.61%
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-8.07%
Beta1.67x
P/FCF (Annual)624.63x
Revenue / Share (TTM)$0.06
ROE (TTM)-130.99%
52-Week Low$0.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LCTXLineage Cell Therapeutics, Inc. | 27.89x | 53.24% | 99.00% | — | $1.64 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement and cell/drug delivery therapies for degenerative diseases. Key pipeline candidates include OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, VAC2 for non-small cell lung cancer, and cell therapies for hearing and vision loss.